Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 13th, 2021

Change is coming to new heart failure guidelines


James Fang, MD, FAHA, and Khadijah Breathett, MD, MS
James Fang, MD, FAHA, and Khadijah Breathett, MD, MS

New treatment guidelines for heart failure are in the final stages of writing, review and approval by the AHA, the American College of Cardiology and other stakeholders. Draft recommendations have not been made public, but members of the guideline committee have strong ideas of what should be included, starting with novel medications and positive health equity strategies to address social determinants of health that so dramatically affect patient care and outcomes.

“There has been some really exciting news in heart failure for patients with reduced ejection and in patients with preserved ejection fraction,” said James Fang, MD, FAHA, John and June B. Hartman Presidential Chair and professor of medicine and chief of cardiovascular medicine at the University of Utah School of Medicine. “Sodium-glucose cotransporter-2 inhibitors were originally designed for patients with diabetes and have had dramatic effects in heart failure. These drugs are a resoundingly safe medication with a very broad indication, so we’re very hopeful they will be addressed.

“It is increasingly clear after several years of exposure that the angiotensin receptor neprilysin inhibitors, or ARNIs, work quite well,” he added. “They are already included in guidelines for HFrEF, and we would hope on the basis of data that have been presented, they may also be addressed in the management of HFpEF.”

Dr. Fang will discuss medication-related changes that could or should be part of the new guidelines during “Where Should New Heart Failure Guidelines Change in 2021?” on Sunday from 3:30-4:30 p.m. EST. Khadijah Breathett, MD, MS, assistant professor of medicine at the University of Arizona Sarver Heart Center, will address some of the health equity strategies needed to make the new guidelines effective for all patients.

There is a growing recognition that effective medications and appropriate prescribing are just a single step in the effective management of heart failure, Dr. Breathett said.

Dr. Breathett outlined circumstances in which patients will not have the best outcomes. Patients who:

  • Cannot afford appropriate medications
  • Lack adequate transportation or childcare to get to care
  • Have not received an understandable explanation of why they should exercise and adjust their diets
  • Do not receive the appropriate care and attention because of provider bias
  • Encounter other barriers to care related to race, ethnicity and socioeconomic status.
  • She emphasized that all of these factors can, and must, be addressed.

“Guidelines do not typically address issues such as bias, structural racism and social determinants of health,” Dr. Breathett said. “We have to start looking at our individual hospital policies and purse strings to identify strategies that help ensure patients get what they need to live fulfilling lives out of the hospital, to live lives of the highest quality possible. That means going beyond the medications we prescribe to improving access.

“We already know how we compare to other countries around the world. We spend the most and we have the worst survival. It doesn’t add up. We have to make conscious decisions on how we are going to address these issues,” she said.

Visit Scientific Sessions Conference Coverage for more articles.


HF.ME.369.

Where Should New Heart Failure Guidelines Change in 2021?

3:30-4:30 p.m. EST

Sunday, Nov. 14

Interesting Stories
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021